《藍籌業績》中生製藥(01177.HK)中期基本盈利升5.2%至17.6億人幣 季度股息2港仙
中國生物製藥(01177.HK)公布截至今年6月底止中期業績,純利12.13億元人民幣(下同),按年跌16%;基本盈利按年升5.2%至17.6億元,每股盈利9.64分。派季度股息每股2港仙,連同已派發第一季度股息每股2港仙,首兩季度合共派發股息每股4港仙。
期內營業額126.48億元,按年升1%,新產品銷售佔集團總收入34.8%。按種類劃分肝病用藥之銷售額約22.49億元,佔收入17.8%,而抗腫瘤用藥收入則為40.18億元,佔收入約31.8%,骨科用藥銷售為10.18億元,抗感染用藥銷售則為7.53億元,呼吸系統用藥銷售為5.97億元。
上半年集團研發總開支約15.41億元,佔收入約12.2%,而次季集團獲得臨床批件8件、生產批件6件及一致性評價獲批3個、申報臨床20件、一致性評價申報1個及申報生產17個。已累計有臨床批件、正在進行臨床試驗和申報生產的在研產品共438件,其中肝病用藥38件、抗腫瘤用藥189件、呼吸系統用藥22件、內分泌用藥24件、心腦血管用藥35件及其他類用藥130件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.